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ABSTRACT 
Colorectal cancer (CRC) is driven by the accumulation of driver mutations, but the 
contributions of specific mutations to different steps in malignant progression is not fully 
understood. In this study, we generated mouse models harboring different combinations of 
key CRC driver mutations (Apc, Kras, Tgfbr2, Trp53, Fbxw7) in intestinal epithelial cells to 
comprehensively investigate their roles in the development of primary tumors and 
metastases. Apc∆716 mutation caused intestinal adenomas and combination with Trp53R270H 
mutation or Tgfbr2 deletion induced submucosal invasion. The addition of KrasG12D mutation 
yielded EMT-like morphology and lymph vessel intravasation of the invasive tumors. In 
contrast, combinations of Apc∆716 with KrasG12D and Fbxw7 mutation was insufficient for 
submucosal invasion but still induced EMT-like histology. Studies using tumor-derived 
organoids showed that KrasG12D was critical for liver metastasis following splenic 
transplantation, when this mutation was combined with either Apc∆716 plus Trp53R270H or 
Tgfbr2 deletion, with the highest incidence of metastasis displayed by tumors with a Apc∆716 
KrasG12D Tgfbr2-/- genotype. RNAseq analysis of tumor organoids defined distinct gene 
expression profiles characteristic for the respective combinations of driver mutations, with 
upregulated genes in Apc∆716 KrasG12D Tgfbr2-/- tumors found to be similarly upregulated in 
specimens of human metastatic CRC. Our results show how activation of Wnt and Kras with 
suppression of TGF-β signaling in intestinal epithelial cells is sufficient for CRC metastasis, 
with possible implications for the development of metastasis prevention strategies.  
 
 
Precis: Findings illuminate how key driver mutations in colon cancer cooperate to drive the 
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide (1,2), and the 
5-year survival rate drops significantly to about 14% for patients with metastasis (3). It is 
therefore extremely important to clarify the biological mechanisms of malignant progression 
in order to identify novel therapeutic target pathways. The gradual accumulation of genetic 
alterations in driver genes is known to cause development and malignant progression of CRC 
and is an established concept of multistep tumorigenesis (4,5). Recent genome-wide 
analyses have confirmed the presence of frequently mutated driver genes in human CRC 
(6,7). Using organoid culture systems, it has been shown that the introduction of genetic 
alterations in driver genes, APC, KRAS, SMAD4, TP53 and PIK3A, in intestinal epithelial 
cells induces tumorigenesis (8-10).  
These driver mutations are classified as cancer signaling pathways (11), and the 
possible mechanisms of each mutation in tumorigenesis have been well studied. For 
example, loss of APC results in Wnt signaling activation, leading to the acquisition of 
stemness (12). KRAS plays a major role in tumorigenesis through the activation of 
RAF-MAPK and PI3K pathways (13). In contrast, TGF-β signaling promotes differentiation of 
epithelial cells, thus playing a tumor suppressor role in CRC (14). Furthermore, FBXW7 is a 
component of the ubiquitin ligase complex that degrades proto-oncogene products, thereby 
functioning as a tumor suppressor (15), and the disruption of Fbxw7 promotes intestinal 
tumorigenesis (16,17). Recent results indicate that mutant p53 alters the gene expression 
globally by gain-of-function mechanism, which promotes tumorigenesis (18,19).  
Moreover, the effects of simultaneous mutations in combination on CRC have also been 
genetically studied. It has been shown that the suppression of TGF-β pathway or expression 
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of mutant p53 in Apc∆716 mice induces the submucosal invasion of intestinal tumors (20-22). 
Moreover, the Kras mutation in addition to Apc and Trp53 mutation causes invasion and 
metastasis (23,24). However, despite these findings from genetic studies, the big picture 
regarding how specific combinations of driver mutations promote each step of malignant 
progression in the primary tumors and metastatic foci remains unclear.  
In the present study, we generated mouse models carrying the Apc∆716 mutation together 
with conditional mutant alleles of KrasG12D, Trp53R270H, Tgfbr2-/- or Fbxw7-/- in various 
combinations and examined their intestinal tumor phenotypes. Using these mouse models 
and allografts of tumor-derived organoids, we found the specific combinations of the driver 
mutations that were responsible for submucosal invasion, epithelial-mesenchymal transition 
(EMT)-like morphology, intravasation and metastasis. Particularly, the combinations including 
Apc∆716 KrasG12D Tgfbr2-/- mutations caused efficient liver metastasis. Moreover, RNA 
sequencing analysis corroborated the distinct expression profiles for the specific mutational 
combinations that are associated with distinct malignant phenotypes in both mice and human. 
Accordingly, targeting the pathways that regulate specific progression processes will be 
effective for the prevention of CRC metastasis.  
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Materials and Methods 
Mouse experiments 
Apc∆716, Fbxw7flox/flox and villin-CreER mice were previously described (25-27). 
Tgfbr2flox/flox, Trp53LSL·R270H and KrasLSL•G12D mice were obtained from the Mouse Repository 
(NCI-Frederick, Frederick, MD) (28-30). Primer sequences for genotyping are previously 
reported except for Trp53 forward primer, 5’-CCTGCCAGCTCCGAAAGATT-3’. The genetic 
background of all strains used in this study is C57BL/6. All mice were treated with Tamoxifen 
(Tam) i.p. at 4 mg/mouse once a week from 8 weeks of age for 4 weeks. For the survival 
curve analysis, mice were observed until 270 days of age, and the mice were euthanized 
when they showed a moribund phenotype. The total numbers of polyps in both the small 
intestine and colon were scored at 13-16 weeks of age (n=3-5 for each genotype). 
NOD/Shi-scid Il2rg-/- mice (NSG mice) and C57BL/6 mice were purchased (CIEA, Japan). All 
animal experiments were performed with the protocol approved by the Committee on Animal 
Experimentation of Kanazawa University.  
 
Histology and immunohistochemistry  
The primary intestinal tumors and liver metastasized tumors were fixed in 4% 
paraformaldehyde, paraffin-embedded, and sectioned at 4-µm thickness. The sections were 
stained with H&E or Masson’s trichrome stain. Antibodies against E-cadherin (R&D Systems), 
αSMA (Sigma), F4/80 (Serotec), CD3ε (Santa Cruz Biotechnology), Ki67 (Life Technologies), 
Lyve-1 (Acris Antibodies GmbH, Germany), vWF (DakoCytomation, Denmark), Snail2 (Bioss), 
CD4, CD8 and CD45R (BD Pharmingen) were used as the primary antibody. Staining signals 
were visualized using the Vectastain Elite Kit (Vector Laboratories). For fluorescent 
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immunohistochemistry, Alexa Fluor 594- or Alexa Fluor 488- conjugated antibodies 
(Molecular Probes) were used as the secondary antibody. The histological classification of 
the tumors was performed according to the Japanese Classification of Colorectal Carcinoma 
(31).  
The mean Ki67 labeling indices were calculated as the number of Ki67 positive cells per 
total number of tumor cells by counting 5 independent microscopic fields (×200) for 3 
independent tumors per mouse (n=3) or 3-8 independent foci of liver metastasized tumors 
(NSG mice n=3 for each, C57BL/6 mice n=1-5).  
The immunostaining-positive areas for F4/80, αSMA and CD3ε in the microscopic fields 
were measured using the Hybrid cell count software program of All-In-One microscope 
(Keyence, Japan). For the primary tumors, the ratio of the αSMA immunostaining-positive 
area was calculated from 3-5 polyps per mouse (n=3). For the liver metastasized tumors, the 
ratios of αSMA, F4/80 and CD3ε immunostaining-positive areas were calculated from 3-12 
foci per mouse (NSG mice n=3, C57BL/6 mice n=1-5).  
 
Scoring invasion efficiency and solitary cells  
The total numbers of invading polyps in submucosa and total polyps were counted on the 
H&E staining sections of whole intestine, and the invasion efficiency was calculated (n=4-5). 
Solitary tumor cells were detected by immunohistochemistry for E-cadherin, and the numbers 
of solitary cells were counted on the sections (n=4-18) while the mean numbers were 
calculated per 1-mm2 area using the Hybrid cell count software program (Keyence).  
 
Organoid culture and transplantation experiments  
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The organoid cultures were prepared from small intestinal tumors, as previously 
described (22). Authentication of the organoid cells was done by genotyping for the 
respective combined mutations. Cryopreserved stocks were established after testing, and 
experiments were performed within 5-10 passages following thaw of frozen stocks. 
Mycoplasma testing was done by indirect immunofluorescence test and nested PCR. The 
cultured organoids were mechanically dissociated, and 3 × 105 organoid cells were injected 
with Matrigel into the spleen of NSG mice (n=3-5) or C57BL/6 mice (n=4-18). At four weeks 
after transplantation, the liver and lung were examined histologically. The multiplicity of 
metastatic foci in the liver was scored by the measurement of the metastasized tumor areas 
on H&E sections and the calculated percentages per total liver (NSG, n=3-5; C57BL/6, 
n=5-12).  
 
Next-generation RNA sequencing  
Total RNA was extracted from organoid cells using an RNeasy plus Micro kit (Qiagen). 
RNA-Seq Libraries were prepared using a SureSelect Strand Specific RNA Reagent Kit 
(Agilent Technologies) according to the manufacturer’s protocol. Thirty-six bp of single-end 
sequencing was performed using an Illumina HiSeq3000 (Ilumina). Obtained reads were 
aligned to UCSC mm10 using tophat2. For the expression estimation, we counted the 
number of reads, which uniquely mapped to the exon of RefSeq transcripts, and calculated 
the reads per kilo-base of exon model per million mapped reads (rpkm) as the expression 
value. The sequencing data were deposited in the DNA Data Bank of Japan (DDBJ, 
accession #DRA005647). Clean reads that average quality scores for all libraries were more 
than Q30 were aligned to the mouse reference (Ensembl 85) using TopHat2 (32).   
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Hierarchical clustering and GO term analysis  
Gene expression quantification was performed using Cufflinks (33). Differential 
expression analysis between samples with replicates was performed using Cuffdiff with the 
cut-off set at P < 0.01 and ≥ 1.5-fold change. Hierarchical clustering for selected genes were 
analyzed with MeV (http://mev.tm4.org) using Euclidean distance and complete linkage 
method. Functional annotation for module members were performed by DAVID (34), and 
relevant gene ontology (GO) terms were selected with a cutoff of P < 0.01.  
 
Processing genomic data from The Cancer Genome Atlas (TCGA) project 
We used publicly available, level 3 data of TCGA in the current study. Clinical information 
and mRNA expression data obtained by RNA sequencing (RNAseq) of the TCGA samples 
were downloaded from the USCS Cancer Browser (https://genome-cancer.ucsc.edu). The 
patients’ clinical data and molecular subtype status of the tumors were referred from the 
TCGA database (6). Among colorectal cancer samples, 343 tumor samples that included 
RNAseq data and metastasis information (M0, n=285; M1, n=58) were analyzed for the 
current study. 
 
The principal component analysis (PCA)  
The rpkm values from RNA sequencing of intestinal tumor organoids were subjected to 
quantile normalization and 5000 genes with the highest variances were input to PCA. PCA 
was performed using the prcomp function implemented in the R software 
(https://www.r-project.org).  
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Statistical analysis  
The data were analyzed using an unpaired t-test and are presented as the means ± 
standard deviation (s.d.). A value of P < 0.05 was considered as statistically significant. The 
significance of the differences of RNA expressions according to same or more than two 
groups was calculated by the Wilcoxon rank sum test. For RNAseq data, statistical analyses 
and data presentations were performed in R language 3.1.3 (http://www.r-project.org) 
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Results 
Generation of mouse models carrying driver mutations in combination  
We crossed Apc∆716 (A), Kras+/LSL-G12D (K), Tgfbr2flox/flox (T), Trp53+/LSL-R270H (P), Fbxw7flox/flox 
(F) and villin-CreER mice to generate compound mutant mice carrying driver mutations in 
different combinations (Fig. 1A and B). These are frequently mutated genes in human CRC 
(6,7). Of note, missense-type mutations of p53 are found in about 50% of human CRC (6), 
and we recently showed that mutant p53R270H induces the submucosal invasion of intestinal 
tumors (22). Accordingly, we used Trp53R270H mice in this study to examine the 
gain-of-function mechanism of mutant p53. In all mice, intestinal tumors were initiated by 
somatic loss of wild-type Apc, which causes Wnt signaling activation (25). The treatment of 
compound mice with tamoxifen (Tam) induced genetic alterations in conditional alleles in an 
intestinal epithelia-specific manner, and we confirmed the Tam-induced recombination in the 
intestinal tumor cells (Supplementary Fig. S1). 
Although none of compound mice developed spontaneous metastasis (see below), the 
mean life spans were decreased depending on the increased numbers of driver mutations 
(Fig. 1C), suggesting that the accumulation of driver mutations affects systemic conditions 
through secreted factors.  
 
Increased multiplicity of intestinal tumors by Apc∆716 KrasG12D combination 
We examined the number and size of intestinal polyps in A, AK, AKP, AKT, ATP, AKTP 
and AKTPF mice. Intestinal tumors of other genotype mice with the Fbxw7 mutation were not 
polypotic and thus uncountable (see below). Notably, the polyp number increased 
significantly in mice that carried the AK combination, i.e. AK, AKP, AKT, AKTP and AKTPF, in 
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comparison to that in A and ATP mice, indicating that Kras activation increases the 
multiplicity of tumors (Fig. 1D and E). Interestingly, the ratio of small polyps (<1 mm) 
dramatically increased in mice carrying AK combination (Fig. 1F), and most small adenomas 
were located in the upper part of the mucosa without connecting to the crypt bottom 
(Supplementary Fig. S2). Therefore, these small adenomas in KrasG12D mice may be 
eliminated by shedding to the lumen, which may explain the increase in the ratio of small 
polyps. We previously showed that Apc∆716 mouse tumor cells cannot survive without 
generation of COX-2-expressing microenvironment (35,36). Thus, it is possible that Kras 
activation contribute to the survival of tumor cells through the generation of such 
microenvironment.  
 
Submucosal invasion by Apc∆716 Trp53R270H and Apc∆716 Tgfbr2-/- combinations 
Histological types of all genotype mouse tumors are shown in supplementary Table S1. 
Notably, mice carrying AP or AT mutations, i.e. AKP, ATP, AKT, ATPF, AKTF, AKTP and 
AKTPF mice, developed adenocarcinomas with invasion to submucosa or deeper, while 
invasive tumors were not found in A, AK and AKF mice (Fig. 2A and B). These results are 
consistent with the previous findings that TGF-β signaling suppression or mutant p53R270H 
expression induces submucosal invasion intestinal tumors (20-22). 
Notably, the ratio of stromal volume was significantly increased in the invaded 
submucosal area with the increased number of αSMA-expressing myofibroblasts in 
comparison to those in mucosal area regardless of mutation types (Fig. 2A and C). Increased 
collagen fiber deposition detected by Masson Trichrome staining was consistently found in 
the submucosal invasion area (Supplementary Fig. S3A). These results indicate that 
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desmoplastic reaction is induced in the submucosa but not in the mucosa. It has been shown 
that such fibrotic reactive stroma plays a role in malignant progression through the secretion 
of various factors including TGF-β and Wnt ligands (37). Tumor cells may therefore acquire 
malignant characteristics in the submucosa by exposure to desmoplastic microenvironment.  
Interestingly, the proliferation rates of tumor cells were significantly lower in the 
submucosal area than in mucosal area, possibly due to the effect of desmoplastic stroma (Fig. 
2D; Supplementary Fig. S3B). We noted no significant difference in the proliferation rates in 
the mucosa of all genotypes compared with that in simple Apc∆716 mouse adenomas, 
indicating that any of the driver mutations does not accelerate the proliferation in primary 
tumors.  
 
Epithelial-mesenchymal transition (EMT)-like morphology in submucosa and mucosa 
by distinct combinations  
EMT is a hallmark of cancer malignancy (38). We found tumor cell clusters that had lost 
their glandular architecture and solitary tumor cells in the submucosa, which showed the 
nuclear accumulation of the EMT marker Snail2 (Fig. 3A; Supplementary Fig. S3C). Of note, 
these invasive tumor cells still expressed E-cadherin, so we classified them as “EMT-like”. 
Importantly, the number of solitary cells in the submucosa was markedly high in AKP, AKT, 
AKTP, AKTF and AKTPF mouse tumors that carried AKP or AKT combination but rarely 
found in ATP and ATPF mice (Fig. 3A and B right). These results indicate that Kras activation 
together with mutant p53R270H expression or TGF-β suppression can induce EMT-like 
morphology when tumor cells are exposed to a desmoplastic microenvironment in 
submucosa. In contrast, solitary tumor cells were found in the mucosal area of AKF, AKTF 
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and AKTPF mice that carried AKF combination (Fig. 3A and B left), suggesting that the 
combination of Kras and Fbxw7 mutations induces EMT-like morphology without the support 
of a desmoplastic microenvironment, although AKF combination is not sufficient for invasion.  
Importantly, intravasation into the Lyve-1-expressing lymph vessels was found in AKT, 
AKTP and AKTPF mouse tumors but rarely found in other genotype mice (Fig. 3C). 
Furthermore, intravasation to the blood vessels was also found in the AKTPF mice. The AKT 
combination may therefore induce intravasation with higher efficiency than the AKP or AKF 
combination.  
 
Distinct histological type and accelerated tumorigenesis by Apc∆716 KrasG12D Fbxw7-/- 
combinations  
It has been shown that FBXW7 plays a role in the differentiation of intestinal epithelia 
(16,17), suggesting that Fbxw7 mutation may alter the tumor morphology. Interestingly, the 
histological type of AKF, AKTF and AKTPF genotype mouse tumors that included the AKF 
combination mutations was villous-type, while other genotype mouse tumors were 
glandular-type (Supplementary Fig. S4A). Because it was technically difficult to assess the 
tumor multiplicity of AKF common mice, the tumor distribution was measured by the length 
ratio on histology sections (Supplementary Fig. S4B). Notably, the tumor distribution was 
significantly increased in the AKF and AKTF mice compared with other genotype mice that 
did not carry the AKF combination (Supplementary Fig. S4B and S4C). These results indicate 
that the combination of Kras activation and Fbxw7 disruption accelerates tumor growth in 
addition to inducing EMT-like morphology, and these properties are independent of the 
invasion ability.  
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Efficient liver metastasis by the Apc∆716 KrasG12D Tgfbr2-/- combination 
We detected no spontaneous metastasis in any genotype mice examined, indicating that 
the accumulation of these driver mutations is not sufficient for metastasis. We therefore 
established organoids from the tumors of A, AK, AP, AT, ATP, ATPF, AKP, AKT, AKTF, 
AKTP and AKTPF mice and transplanted them to the spleens of immunodeficient NSG mice 
as well as immunocompetent C57BL/6 mice to examine their ability of metastasis to the liver 
(Fig. 4A). At 4 weeks after spleen injection to NSG mice, tumor organoids with ≥3 mutations 
except for ATP (i.e. AKP, AKT, ATPF, AKTF, AKTP and AKTPF) developed metastatic 
tumors with 100% incidence. Among them, the multiplicity of metastasis was significantly 
higher in the AKT common organoids, i.e. AKT, AKTF, AKTP and AKTPF, than in those of 
AKP or ATPF (Fig. 4B). The organoids carrying AKT combination efficiently formed 
metastatic tumors also in C57BL/6 mice, while the incidences of metastasis of AKP and 
ATPF in C57BL/6 mice were 10% and 0%, respectively (Fig. 4A, C and D). These results 
indicate that Wnt activation, Kras activation and TGF-β suppression by AKT mutations are 
the core combination for efficient liver metastasis. Notably, additional mutations in Trp53 and 
Fbxw7 to AKT, i.e. AKTP and AKTPF, induced the development of lung metastasis after the 
spleen injection of organoids, which was not found in other genotypes (Fig. 4A). Furthermore, 
AKTPF organoids showed the highest mean multiplicity of liver metastasis among the AKT 
common organoids.  
 
Desmoplasia and T cell infiltration in metastasized tumors  
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Histologically, metastasized tumors were diagnosed as moderately to poorly 
differentiated adenocarcinomas with desmoplastic reaction in the stroma consisting of 
αSMA-positive myofibroblasts (Fig. 4E and F). The desmoplastic reaction was induced in all 
invaded tumors, suggesting that the AKP or AKT combination is sufficient to induce fibrotic 
responses in metastatic lesions. In contrast to the primary tumors, the mean proliferation rate 
of tumor cells increased gradually from AKP to AKT, AKTF, AKTP and AKTPF (Fig. 4G; 
Supplementary Fig. S5). Of note, macrophages, CD4+ and CD8+ T cells, and B cells were 
infiltrated into the metastasized tumors at the similar levels, regardless of the tumor 
genotypes, whereas T cell infiltration was rarely found in the primary tumors of the same 
genotype mice (Fig. 4H and I; Supplementary Fig. S5). Accordingly, the interaction with 
microenvironment in the metastasized tumors contributes to the induction of the host immune 
response to tumor cells, although the underlying mechanism remain to be investigated.  
 
Identification of common genes for metastasis induced by the Apc∆716 KrasG12D Tgfbr2-/- 
combination  
To examine whether genotype-related malignant phenotypes are associated with distinct 
expression profiles, we next performed RNA sequencing of the tumor organoids for the ATP, 
AKP, AKT, AKTP and AKTPF genotypes that showed submucosal invasion in the primary 
tumors. Notably, a principal component analysis (PCA) indicated that expression profiles of 
tumors carrying the KrasG12D mutation (AK common, i.e., AKP, AKT, AKTP and AKTPF) were 
divergent from that of ATP (Fig. 5A left), which reflected the fact that Kras activation is 
required for metastasis. Furthermore, the expression profiles of AKT common (AKT, AKTP 
and AKTPF) organoids were distinct from that of AKP (Fig. 5A center), which reflected the 
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high metastatic ability of AKT common organoids compared with AKP. We also found the 
evolutional expression changes from AKT to AKTPF via AKTP (Fig. 5A right). These results 
suggest that expression changes induced by AKT mutations causes efficient metastasis, and 
additional mutations in Trp53 and Fbxw7 accelerate malignancy, which is consistent with the 
results of phenotype analyses (Fig. 5B).  
We next extracted 363 differentially expressed genes (DEGs) in AKT common genotype 
tumors by selection of overlapping genes in AKT, AKTP and AKTPF versus A, respectively 
(Fig. 5C; Supplementary Table S2). Gene ontology (GO) term analysis using AKT common 
DEGs indicated significantly enriched pathways relating to angiogenesis, signal transduction, 
hypoxia and epithelial morphogenesis, suggesting the role of these pathways in AKT 
combination-induced metastasis (Fig. 5D). Hierarchical clustering analysis indicated that 
expression pattern of ATP was divergent from that of AKT common genotypes (Fig. 5E). 
Although expression of AKP was distinct from AKT common, we found 175 overlapping 
DEGs in AKT common and AKP but not with ATP (Fig. 5E−G). These results are consistent 
with those found by PCA (Fig. 5B). Notably, the expression profile of AK tumors was similar 
to that of AKT common. We found that organoids from AK tumors but not simple ApcΔ716 
tumors formed submucosal tumors with desmoplastic reactions when they were injected 
directly into colonic submucosa (Supplementary Fig. S6). Taken together, these results 
suggest that the AK combination significantly contributes to the AKT-induced malignant 
phenotype. 
We thus classified 363 AKT common DEGs to four clusters of AKT (CL1, CL2, CL3 and 
CL5 in Fig. 5F) (Supplementary Table S2), and performed hierarchical clustering analysis. As 
expected, 73 genes classified to CL5 showed expression patterns specific to the AKT 
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common genotypes, which were not overlapped with AKP and ATP (Fig. 6A, B). Among 73 
AKT-common genes, we selected 60 genes, 21 upregulated and 39 downregulated, which 
were annotated in the TCGA CRC database, and extracted expression data of these 60 
genes. Importantly, the mean expressions of upregulated AKT-common genes were 
significantly higher in human CRC with metastasis (M1) than those without metastasis (M0), 
suggesting that AKT-common signature is important also for human CRC metastasis (Fig. 
6C). Moreover, we found that expression levels of R3HDML and SYT7 were significantly 
upregulated in M1 than M0 CRC tissues, while those of PSME1 and TMEM150C were 
downregulated, which were consistent with those found in the AKT-common profile (Fig. 6B, 
C). Of note that SYT7, a calcium sensor for synapse exocytosis, plays a role in cell migration 
(39,40). Accordingly, it is possible that upregulated genes in AKT-common profile will be 
effective therapeutic targets for CRC metastasis. 
 
Discussion  
To understand how the specific combinations of driver mutations promote each step for 
CRC malignant progression, we performed comprehensive phenotype characterization of the 
primary intestinal tumors and liver metastasis in mouse models that carried various driver 
mutations in combination (Fig. 7). Among the driver genes examined in this study, the 
activation mutation of Kras is essential for EMT-like morphology and metastasis. This is 
consistent with the previous reports that liver and lung metastasis of human CRC are more 
likely to develop in patients whose tumors have KRAS mutations (41,42). In addition, a recent 
genetic study indicated that the continuous expression of activated Kras is required for the 
maintenance of invasive and metastatic disease (23). In the present study, we found that the 
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KrasG12D mutation induced EMT-like morphology of Apc∆716 mouse tumors when combined 
with mutations in either of Fbxw7-/-, Tgfbr2-/- or Trp53R270H. Furthermore, Kras activation 
promoted intravasation and efficient liver metastasis when combined with Apc∆716 and 
Tgfbr2-/- mutations (AKT common) (Fig. 7). In contrast, the combination of Apc∆716 and 
KrasG12D mutations was not sufficient for invasion, indicating that malignant progression by 
Kras mutation requires other driver mutations in combination.  
We previously showed that either TGF-β signaling suppression or mutant p53R270H 
expression induces submucosal invasion of Apc∆716 mouse tumors (20-22). Consistently, 
compound mice that carried AT or AP mutations in their genotypes consistently developed 
invasive adenocarcinoma. Unexpectedly, however, simultaneous mutations of Tgfbr2-/- and 
Trp53R270H did not induce further intravasation or metastasis, and the expression profile of 
ATP organoids was divergent from that of metastatic AKP and AKT organoids. These results 
confirm the requirement of a Kras mutation in addition to either TGF-β suppression (AKT) or 
p53 mutation (AKP) for metastasis of CRC (Fig. 7).  
On comparing phenotypes between AKP and AKT tumors, AKT showed markedly more 
advanced malignancy, such as lymph vessel invasion and significantly higher incidence and 
multiplicity of metastasis in the liver. Interestingly, the expression profiles of AKTP and 
AKTPF more closely resemble that of AKT than AKP; therefore, we would therefore like to 
propose that Wnt activation, Kras activation and TGF-β suppression (i.e. AKT) are core 
combination pathway for efficient metastasis, and the selected AKT common DEGs play a 
role in this process (Fig. 6B). Importantly, the mean expression level of AKT-common 
upregulated genes was significantly increased in human CRC with metastasis (M1), 
suggesting that AKT-common signature is important also for metastasis of human CRC. 
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Moreover, we found that Syt7 is upregulated both in AKT-common genes and human CRC 
with metastasis. Synaptotagmin (Syt) is a well-established calcium sensor for 
calcium-induced exocytosis of synaptic vesicles (39). Notably, it has been shown that 
Syt7-mediated vesicle fusion regulates the chemotaxis of leukocytes (40). Accordingly, it is 
possible that Syt7 plays a tumor-promoting role by accelerating the migration of CRC cells.  
Accordingly, activated pathways by AKT-common mutations may play a role in malignant 
progression of human CRC. 
In contrast, it has been shown that the TGF-β pathway is activated in the invasive tumor 
cells of Apc Trp53Null KrasG12D mice (23) and that TGF-β signaling in the stroma facilitates 
tumorigenesis through the promotion of fibrosis and immune evasion (43). Accordingly, it is 
possible that TGF-β signaling in the stroma plays a role in the malignant progression of AKT 
tumor cells that have lost their TGF-β signaling. 
In this study, we also found that a desmoplastic reaction is induced in submucosal 
tumors and liver metastasis, while such fibrotic reactions were rarely found in non-invading 
mucosal tumors of the same mice. Notably, the histological features of tumors were 
distinctively more malignant in the invasive and metastatic lesions, suggesting that 
desmoplastic stroma contributes to the induction of malignant phenotypes. It has been 
reported that fibrosis with the deposition of type I collagen promotes metastasis by inducing 
the proliferation of dormant cells via integrin signaling (37,44,45), and collagen crosslinking in 
the stroma results in the promotion of invasion and metastasis (46). Therefore, it is possible 
that EMT-like morphology and metastasis of AKT tumors are induced by cooperation of driver 
mutations and fibrotic microenvironment.  
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The disruption of Fbxw7 increased the number of intestinal tumors in ApcMin mice (16,17), 
however, its role in malignant progression remains unclear. In this study, we showed that the 
combination of the Fbxw7-/- and KrasG12D mutations (AKF) induced EMT-like morphology in 
mucosal tumors without support of fibrotic microenvironment (Fig. 7). It has been shown that 
Fbxw7 plays a role in stem cell regulation, and its deletion accelerates the self-renewal 
activity of stem cells (47). Furthermore, there is a direct link between EMT and the gain of 
epithelial stem cell properties (48). It is therefore possible that Fbxw7 disruption leads to 
EMT-like morphology through the acquisition of stem cell properties, which may contribute to 
the increased multiplicity of metastasis of AKTPF tumors compared with AKTP.  
In this study, we did not find spontaneous metastasis to distant organs in any genotype 
mice, even if tumor cells can invade into vessels and metastasize to liver from spleen (Fig. 7). 
It is therefore possible that additional genetic or epigenetic alteration(s) are required to 
overcome physical stresses in the blood stream and escape from immune attack, which are 
required to be survived as circulating tumor cells (Fig. 7) (37). 
Microsatellite instability (MSI)-high CRC is associated with an increased level of immune 
cell infiltration (49), therefore, MSI-high CRC responds to immune checkpoint blockade (50). 
However, the association with tumor-infiltrating lymphocytes was also evident in 
microsatellite-stable CRC tumors (7), indicating that non-MSI CRC also can induce an 
immune reaction. In the present study, we found that both CD4+ and CD8+ T cells infiltrated 
into metastasized tumors of C57BL/6 mice at the similar level among all genotypes, although 
T cell infiltration was rarely detected even in the invasive area of the primary tumors. These 
results suggest a mechanism of the microenvironment in the metastasized tumors to induce 
immune responses against non-MSI CRC cells, although further studies will be needed. This 
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mechanism is particularly important for understanding tumor immunity, which will help 
develop therapeutic strategies for preventing CRC metastasis in the future.  
In conclusion, we constructed mouse models with multiple combinations of driver 
mutations and performed the comprehensive characterization of the primary and metastatic 
tumors. Suppression of the TGF-β pathway or expression of mutant p53 induces submucosal 
invasion, and additional Kras mutation activation is required for further malignant progression 
including EMT-like morphology, intravasation and metastasis. In contrast, the combination of 
Fbxw7 inhibition and Kras activation induces EMT-like morphology, possibly through 
increased stemness. Finally, Wnt activation, Kras activation and TGF-β suppression 
represent important combination for efficient metastasis, which is corroborated by the RNA 
sequencing analysis. Accordingly, pathways activated by the AKT common DEGs may be 
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Figure legends 
Figure 1. The generation of mouse models and intestinal polyp phenotypes. (A) Schematic 
drawing of mutant alleles of each driver gene (top). Schedule for tamoxifen (Tam) treatment 
(bottom). (B) Combinations of driver gene mutations in the respective genotype mice. (C) The 
survival curves of each compound mutant strain are shown. (D) Size classification of 
non-invasive and invasive intestinal polyps of the indicated compound mutant mice (n=3). 
Each dot shows an individual polyp. (E) The number of the intestinal polyps in indicated 
compound mutant mice (mean ± s.d.). Asterisks, p < 0.05. (F) Ratio of intestinal polyps φ ≥ 1 
mm (orange) and φ < 1mm (blue) in diameter in the indicated genotype mice.   
 
Figure 2. Submucosal invasion of the primary intestinal tumors in mice carrying AP or AT 
mutations. (A) Representative histology sections of the intestinal polyps of the indicated 
genotype mice (top, H&E low magnification; middle, high magnification of the boxed area in 
top; bottom; αSMA immunostaining). The dotted lines in middle and bottom indicate the 
location of the muscularis mucosae. The arrowheads indicate invading tumor cells in the 
submucosa. Bars, 200 µm. (B) The efficiency of submucosal invasion in the indicated 
genotype mice (mean ± s.d.). ND, not detected. Asterisks, p < 0.05. (C) Percentages of 
αSMA immunostaining positive area in mucosal (top) and submucosal (bottom) tumors in the 
indicated genotype mice (mean ± s.d.). Asterisks, p < 0.05 versus mucosal area for each 
genotype. (D) Percentages of Ki67-positive tumor cells in mucosal (top) and submucosal 
(bottom) tumors in the indicated genotype mice (mean ± s.d.). Asterisks, p < 0.05 versus 
mucosal area for each genotype.   
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Figure 3. EMT-like morphology and intravasation of the primary tumors in mice carrying AKP 
or AKT mutations. (A) Representative immunohistochemistry sections for E-cadherin in the 
submucosal invasion area of AKP, AKT, ATP, AKTP, AKTF, ATPF and AKTPF mouse 
tumors and the mucosal area of AKF mouse tumor. The insets indicate enlarged images of 
solitary or clustered tumor cells. The arrowheads indicate the solitary or clustered tumor cells. 
Bars, 100 µm. (B) The mean umber of solitary tumor cells per mm2 area in mucosal (left) and 
submucosal (right) tumors of the indicated genotype mice (mean ± s.d.). Each dot indicates 
individual mice. Asterisks, p < 0.05. (C) Representative photographs of fluorescence 
immunohistochemistry for Lyve-1 or vWF (green), E-cadherin (red), and nuclear 
counterstaining with DAPI (blue) in the submucosal region of intestinal tumors of the 
indicated genotype mice. The arrowheads indicate the E-cadherin positive tumor cells in the 
Lyve-1-posibive lymph vessels or vWF-positive capillary vessel. The insets indicate the 
enlarged images of tumor cells with intravasation. Bars, 200 µm.   
 
Figure 4. Liver metastasis of tumor organoids derived from mice carrying AKP and AKT 
mutations. (A) Incidence of liver and lung metastasis at 4 weeks after transplantation of the 
indicated genotype organoids to spleen of C57BL/6 and NSG mice. NT, not tested because 
of no metastasis in NSG mice. (B, C) Multiplicity of liver metastasis calculated by 
percentages of metastasized tumor foci in the liver on the H&E sections in NSG mice (B) and 
C57BL/6 mice (C) (mean ± s.d.). Each dot indicates individual mice. Asterisks, p < 0.05. (D) 
Representative macroscopic photographs (top) and histology sections (H&E, bottom) of livers 
of C57BL/6 mice transplanted with the indicated genotype organoids. The arrowheads 
indicate metastatic foci. Bars, 1 cm (top) and 1 mm (bottom). (E) Representative photographs 
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of liver metastasis of the indicated genotype organoids in C57BL/6 mice. (top, H&E low 
magnification; middle, enlarged high magnification images of the boxed area in top; bottom, 
αSMA immunostaining). Bars, 200 µm. (F) Ratio of αSMA immunostaining-positive area in 
liver metastasis tumors (mean ± s.d.). (G) Ratio of Ki67-positive tumor cells in liver 
metastasis tumors (mean ± s.d.). (H, I) Ratio of immunostaining-positive area for F4/80 (H) 
and CD3ε (I) in liver metastasis tumors (mean ± s.d.). Each dot indicates individual mice. 
 
Figure 5. Gene expression profiles associated with driver mutation-induced malignant 
progression phenotypes. (A) A principal component analysis (PCA) for sequence results of A, 
ATP, AKP, AKT, AKTP and AKTPF organoids. AKP, AKT, AKTP and AKTPF are included in 
the AK common group (left, blue), and AKT, AKTP and AKTPF are included in the AKT 
common group (center, blue). (B) Schematic model of the evolutionary changes in the gene 
expression pattern in association with malignant progression phenotypes based on the 
results of the PCA in (A). (C) Venn diagram for overlapping DEGs in AKT, AKTP and AKTPF 
versus A. The number of extracted genes and cluster names are indicated. (D) Functional 
annotations by GO term analysis using 363 AKT common DEGs are shown (-log of p values). 
(E) Hierarchical clustering analysis of the AKT common DEGs is shown as fold-changes of 
RPKM compared to the mean. (F) Venn diagram for overlapping DEGs in AKT, ATP and AKP 
versus A. The number of extracted genes and cluster names (CL1-7) are indicated. (G) The 
number of AKT common DEGs overlapped in each cluster of AKT DEGs in (F).  
 
Figure 6. Extracted DEGs specific to AKT common genotype tumors. (A) Hierarchical 
clustering heatmaps of the AKT common DEGs that are classified to the respective clusters 
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of AKT (CL1, CL2, CL3 and CL5) are shown as fold-changes of RPKM compared to the 
mean. (B) The clustering heatmap of the AKT common DEGs classified to CL5 cluster in (A) 
is shown with gene symbol. Gene symbols indicated by red are upregulated or 
downregulated also in human CRC with metastasis. (C) Expression analysis of the mean 
AKT-common upregulated genes (AKT-up) and that of AKT-common downregulated genes 
(AKT-down), and the indicated genes in human CRC tissues with metastasis (M1) or without 
metastasis (M0). P values are indicated in red. 
 
Figure 7. A schematic drawing of the genotype-phenotype relationship in multistep 
tumorigenesis. Metastasis phenotypes (right) are based on the results of organoid 
transplantation to the spleen. AF and AKF were not examined for the metastasis assay (gray).  
In this study, survival of circulating tumor cells (CTC) was not evaluated for the respective 
genotypes. 
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